Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET
Company Participants
Katie Plante – Manager of Investor Relations
Barry E. Greene – Chief Executive Officer
Chris Benecchi – Chief Business Officer
Laura Gault – Chief Medical Officer
Kimi Iguchi – Chief Financial Officer
Mike Quirk – Chief Scientific Officer
Conference Call Participants
Anupam Rama – J.P. Morgan
Salveen Richter – Goldman Sachs
Yasmeen Rahimi – Piper Sandler
Jay Olson – Oppenheimer
Ami Fadia – Needham
Brian Abrahams – RBC Capital Markets
Tazeen Ahmad – Bank of America
Uy Ear – Mizuho
Joel Beatty – Baird
Marc Goodman – Leerink
Operator
Good afternoon. Welcome to Sage Therapeutics’ Third Quarter 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Sage’s website at sagerx.com. This call is a property of Sage Therapeutics, and recording, reproduction, or transmission of this call without the expressed written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded.
I would now like to introduce Katie Plante, Manager of Investor Relations at Sage.
Katie Plante
Good afternoon, and thank you for joining Sage Therapeutics’ third quarter 2024 financial results conference call. Before we begin, I encourage everyone to go to the Investors and Media section of our website at sagerx.com, where you can find the press release and slides related to today’s call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please review the risk factors discussed in today’s press release and in our SEC filings for additional details.
We
Read the full article here
